E D Rosenstein1, M J Zucker, N Kramer. 1. Division of Rheumatology and Arthritis and Rheumatic Disease Center, St. Barnabas Medical Center, Livingston, NJ 07039, USA. Erosenstein@sbhcs.com
Abstract
OBJECTIVE: To increase awareness of giant cell myocarditis (GCM), its pathogenesis, and treatment. METHODS: Review of relevant publications from the English-language literature. RESULTS: GCM is a rare, frequently fatal inflammatory disorder of cardiac muscle of unknown origin, characterized by widespread degeneration and necrosis of myocardial fibers.Congestive heart failure and ventricular tachycardia are common clinical manifestations. GCM occurs primarily in previously healthy adults, although it is frequently associated with various systemic diseases, primarily of autoimmune causes. The inflammatory infiltrate is characterized by the presence of multinucleated giant cells and is distinct from cardiac sarcoidosis. Animal models of GCM are similar to models of other autoimmune disorders such as rheumatoid arthritis. The prognosis, which is poor despite partial responsiveness to immunosuppressive medications, is improved with cardiac transplantation. CONCLUSIONS: The clinical and immunopathogenetic similarities with classical rheumatologic diseases, the differential diagnosis with sarcoidosis and other inflammatory conditions, and the use of standard immunosuppressive medications make GCM a disease process that should be added to the rheumatologist's expertise.
OBJECTIVE: To increase awareness of giant cell myocarditis (GCM), its pathogenesis, and treatment. METHODS: Review of relevant publications from the English-language literature. RESULTS: GCM is a rare, frequently fatal inflammatory disorder of cardiac muscle of unknown origin, characterized by widespread degeneration and necrosis of myocardial fibers.Congestive heart failure and ventricular tachycardia are common clinical manifestations. GCM occurs primarily in previously healthy adults, although it is frequently associated with various systemic diseases, primarily of autoimmune causes. The inflammatory infiltrate is characterized by the presence of multinucleated giant cells and is distinct from cardiac sarcoidosis. Animal models of GCM are similar to models of other autoimmune disorders such as rheumatoid arthritis. The prognosis, which is poor despite partial responsiveness to immunosuppressive medications, is improved with cardiac transplantation. CONCLUSIONS: The clinical and immunopathogenetic similarities with classical rheumatologic diseases, the differential diagnosis with sarcoidosis and other inflammatory conditions, and the use of standard immunosuppressive medications make GCM a disease process that should be added to the rheumatologist's expertise.
Authors: Angeliki Asimaki; Harikrishna Tandri; Elizabeth R Duffy; Jeffrey R Winterfield; Shannon Mackey-Bojack; Maria M Picken; Leslie T Cooper; David J Wilber; Frank I Marcus; Cristina Basso; Gaetano Thiene; Adalena Tsatsopoulou; Nikos Protonotarios; William G Stevenson; William J McKenna; Shiva Gautam; Daniel G Remick; Hugh Calkins; Jeffrey E Saffitz Journal: Circ Arrhythm Electrophysiol Date: 2011-08-22
Authors: Sophie I Mavrogeni; Petros P Sfikakis; Theodoros Dimitroulas; Loukia Koutsogeorgopoulou; George Markousis-Mavrogenis; George Poulos; Genovefa Kolovou; George Theodorakis; George D Kitas Journal: Rheumatol Int Date: 2018-07-24 Impact factor: 2.631
Authors: Rafael J Argüello; Carlos Vigliano; Patricia Cabeza-Meckert; Rodolfo Viotti; Fernando Garelli; Liliana E Favaloro; Roberto R Favaloro; Rubén Laguens; Susana A Laucella Journal: PLoS Negl Trop Dis Date: 2014-08-21
Authors: Alida L P Caforio; Renzo Marcolongo; Roland Jahns; Michael Fu; Stephan B Felix; S Iliceto Journal: Heart Fail Rev Date: 2013-11 Impact factor: 4.654